Collaborations as a home grown business model

Collaborations as a home grown business model

This is one of the models which many global Pharma companies are eyeing in the current competitive scenario. One of the major countries eyeing the Indian geography today is Japan. Top Japanese drug makers are planning big presence and investments in India, within two years of India’s largest manufacturer, Ranbaxy Laboratories, being taken over by Daiichi Sankyo, the third largest Japanese one. Last week, the $40-billion Mitsui & Co Ltd announced it would acquire a five per cent stake in pharmaceuticals ingredient manufacturer Arch Pharmalabs for `65 crore. The move is to strengthen its contract manufacturing business in the pharmaceutical sector. Mitsui has had a business relationship with Arch for the past four years. The strategic stake sale will help the 1,200-crore Arch to foray into supply of active ingredients and intermediates in the tough Japanese market, as Mitsui will exclusively market Arch’s products in Japan.


http://blogs.veedacr.com/Lists/Posts/Post.aspx?ID=342